上海君实生物医药科技股份有限公司2025 年半年度报告 公司代码：688180 公司简称：君实生物 上海君实生物医药科技股份有限公司 2025 年半年度报告 1 / 208 上海君实生物医药科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 生物医药行业具有研发周期长、投入大、风险高的特点。公司在报告期内不断丰富产品管线， 持续探索药物的联合治疗，快速推进现有临床项目的开展和储备研发项目的开发，营业收入尚不 能覆盖研发费用及其他开支，报告期内公司尚未实现盈利。 报告期内，公司在创新药物的发现、研发、生产和商业化等方面皆有源头创新性、突破性进 展，现金流情况良好，公司核心管理层及研发团队稳定。随着更多在研产品逐步实现商业化以及 已上市产品更多适应症的拓展，公司的持续经营能力将不断提升。 公司致力于创新疗法的发现、开发和商业化。公司积极布局覆盖多项疾病治疗领域的在研产 品管线，未来仍将维持相应规模的研发投入用于在研产品的临床前研究、 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-040 上海君实生物医药科技股份有限公司 2025 年半年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司募集 资金监管规则》《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》和《上海证券交易所科创板股票上市规则》等相关规定，上海君实生物医 药科技股份有限公司（以下简称"公司"）董事会将公司2025年半年度（以下简 称"报告期"）募集资金存放与实际使用情况专项说明如下： 根据中国证监会于2020年5月20日出具的《关于同意上海君实生物医药科技 股份有限公司首次公开发行股票注册的批复》（证监许可〔2020〕940号），公 司获准向社会公开发行人民币普通股87,130,000股，每股发行价格为人民币55.50 元，募集资金总额为人民币4,835,715,000.00元；扣除不含税发行费用人民币 338,736,673.27元，实际募集资金净额为人民 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-041 上海君实生物医药科技股份有限公司 关于变更注册资本、取消监事会并修订《公司章程》及 其附件、修订及制定部分内部管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第四届董事会第十次会议，审议通过了《关于变更注册资本、取消监 事会、修订<公司章程>及其附件的议案》《关于修订及制定部分内部管理制度 的议案》，同日，公司召开第四届监事会第八次会议，审议通过了《关于取消监 事会、废止<监事会议事规则>的议案》。现将有关事项公告如下： 一、变更注册资本相关情况 2025 年 6 月 20 日，公司完成根据一般授权配售新 H 股，按每股 H 股 25.35 港元的配售价格向符合条件的承配人成功配售合计 41,000,000 股 H 股配售股份。 本次配售完成后，公司总股本由 985,689,871 股增加至 1,026,689,871 股，其中 A 股总股本为 ...

上海君实生物医药科技股份有限公司 2025 年度"提质增效重回报"行动方案的 半年度评估报告 为进一步履行社会责任，全方位推动公司经营的持续优化与升级，上海君实 生物医药科技股份有限公司（以下简称"公司"）结合自身发展战略和经营情况， 制定了《上海君实生物医药科技股份有限公司 2025 年度"提质增效重回报"行 动方案》（以下简称"2025 年行动方案"或"本方案"），详细情况参见公司已于 2025 年 3 月 28 日披露于上海证券交易所网站（www.sse.com.cn）的公告。2025 年上半年，公司切实履行并持续评估 2025 年行动方案的具体举措，现将 2025 年行动方案在 2025 年半年度（以下简称"报告期"）内的实施和效果评估情况报 告如下： 一、提升经营效率，加强合规建设，促进高质量发展 公司具备完整的从创新药物的发现和开发、在全球范围内的临床研究、大规 模生产到商业化的全产业链能力，旨在成为立足中国、布局全球的创新医药公司。 公司坚持质量为本、求真务实、诚信合规、追求卓越的企业价值观，致力于通过 源头创新以及合作开发等形式来研发 first-in-class（同类首创）或 best-in ...

Group 1 - The core viewpoint of the article highlights that Junshi Biosciences reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders of the listed company was 413 million yuan, an improvement from a net loss of 645 million yuan in the same period last year [1] - Research and development expenses accounted for 60.39% of the revenue, which is a decrease of 9.12 percentage points compared to the previous year [1]

| 指数 | 最新 | 涨跌幅 | | --- | --- | --- | | 相生指数 | 25524.92 | -1.18% | | 国企指数 | 9148.66 | -1.07% | | 红筹指数 | 4343.85 | -1.02% | 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯：北京时间8月26日16:00，恒生指数收盘下跌304.99点，跌幅为1.18%，报收25524.92点；国 企指数收盘下跌99.34点，跌幅为1.07%，报收9148.66点；红筹指数收盘下跌44.65点，跌幅为1.02%，报 收4343.85点。南向资金当日净流入165.73亿港元。东方甄选跌超11%，蔚来、君实生物跌超6%，中兴 通讯跌近6%，碧桂园跌超5%；中国黄金国际涨超10%，灵宝黄金涨超9%。 （记者 胡玲） ...

Group 1 - The core viewpoint of the article highlights a significant decline in Hong Kong's biopharmaceutical stocks, with notable drops in several companies [2] Group 2 - Junshi Biosciences and Kelun Pharmaceutical both experienced declines exceeding 7% [2] - Innovent Biologics saw a drop of over 4% [2] - WuXi AppTec, Tigermed, and CanSino Biologics all fell by more than 3% [2]

Company Overview - Junshi Biosciences has seen a stock price increase of 71.24% year-to-date, with a recent decline of 0.55% over the last five trading days, a 17.91% increase over the last 20 days, and a 43.96% increase over the last 60 days [2] - The company specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with its main revenue sources being drug sales (84.18%), technology licensing and royalties (12.08%), and other income (3.73%) [2] - As of March 31, 2025, Junshi Biosciences reported a revenue of 5.01 billion yuan, representing a year-on-year growth of 31.46%, while the net profit attributable to shareholders was -2.35 billion yuan, showing a year-on-year increase of 17.01% [2] Market Performance - As of August 25, Junshi Biosciences' stock was trading at 46.80 yuan per share, with a market capitalization of 48.049 billion yuan [1] - The trading volume on August 25 was 2.19 billion yuan, with a turnover rate of 0.62% [1] - The net outflow of main funds was 850,700 yuan, with large orders accounting for 30.05% of purchases and 31.65% of sales [1] Shareholder Structure - As of March 31, 2025, the top ten circulating shareholders included Huaxia SSE Sci-Tech Innovation Board 50 ETF, which held 30.2534 million shares, a decrease of 5.0506 million shares from the previous period [3] - E Fund SSE Sci-Tech Innovation Board 50 ETF held 21.5833 million shares, down by 869,200 shares compared to the previous period [3] - Hong Kong Central Clearing Limited increased its holdings to 14.9956 million shares, an increase of 1.5278 million shares from the previous period [3]

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Junshi Biosciences, indicating a significant level of trading activity and high financing balance [1] - On August 22, Junshi Biosciences experienced a stock price increase of 1.10%, with a total transaction amount of 683 million yuan, and a net financing purchase of 17.69 million yuan [1] - The total financing and securities lending balance for Junshi Biosciences reached 1.273 billion yuan, with the financing balance accounting for 3.60% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs, with 84.18% of its revenue coming from drug sales [2] - For the first quarter of 2025, Junshi Biosciences reported an operating income of 501 million yuan, representing a year-on-year growth of 31.46%, while the net profit attributable to shareholders was -235 million yuan, showing a year-on-year increase of 17.01% [2] - As of March 31, 2025, the number of shareholders of Junshi Biosciences was 29,400, with a slight increase of 0.24% compared to the previous period [2] Group 3 - As of March 31, 2025, among the top ten circulating shareholders of Junshi Biosciences, the Huaxia SSE STAR 50 ETF held 30.25 million shares, a decrease of 5.05 million shares from the previous period [3] - The E Fund SSE STAR 50 ETF held 21.58 million shares, down by 869,200 shares compared to the previous period [3] - Hong Kong Central Clearing Limited increased its holdings to 14.99 million shares, an increase of 152,780 shares from the previous period [3]

Group 1 - The core point of the article highlights that Junshi Biosciences has seen a net financing inflow of 49.2165 million yuan last week, ranking 286th in the two markets [1] - The company had a total financing purchase amount of 498 million yuan and repayment amount of 449 million yuan last week [1] - Junshi Biosciences operates in various concept sectors including biopharmaceuticals, Shanghai sector, FTSE Russell, MSCI China, and innovative drugs [1] Group 2 - Over the past five days, the main capital inflow for Junshi Biosciences was 46.6941 million yuan, with a price increase of 1.0% [1] - In the last ten days, the main capital outflow was 143 million yuan, with a price decrease of 1.54% [1] - Junshi Biosciences, established in 2012 and located in Shanghai, has a registered capital of approximately 985.69 million yuan and a paid-in capital of 14.7 million yuan [1] Group 3 - The company has made investments in 40 enterprises and participated in 40 bidding projects [1] - Junshi Biosciences holds 151 trademark registrations and 115 patent registrations, along with 141 administrative licenses [1]